{Reference Type}: Journal Article
{Title}: Hepatic arterial infusion chemotherapy plus camrelizumab and apatinib for advanced hepatocellular carcinoma.
{Author}: Zuo M;Cao Y;Yang Y;Zheng G;Li D;Shao H;Ma Q;Song P;An C;Li W;
{Journal}: Hepatol Int
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jul 3
{Factor}: 9.029
{DOI}: 10.1007/s12072-024-10690-6
{Abstract}: <B>OBJECTIVE: </B>There is limited information on combination of hepatic arterial infusion chemotherapy (HAIC) and systemic therapy for advanced hepatocellular carcinoma (Ad-HCC). We aim to compare the efficacy and safety of HAIC plus camrelizumab (a PD-1 inhibitor) and apatinib (an VEGFR-2 inhibitor) versus camrelizumab and apatinib for Ad-HCC.<BR><B>METHODS: </B>From April 2019 to October 2022, 416 patients with Ad-HCC who received either HAIC plus camrelizumab and apatinib (TRIPLET protocol, n = 207) or camrelizumab and apatinib (C-A protocol, n = 209) were reviewed retrospectively. The propensity score matching (PSM) was used to reduce selective bias. Overall survival (OS) and progression-free survival (PFS) were compared using the Kaplan-Meier method with the log-rank test. Cox regression analyses of independent prognostic factors were evaluated.<BR><B>RESULTS: </B>After PSM 1:1, 109 patients were assigned to two groups. The median OS of not reached in the TRIPLET group was significantly longer than that of 19.9 months in the C-A group (p < 0.001), while in the TRIPLET group, the median PFS of 11.5 months was significantly longer than that of 9.6 months in the C-A group (p < 0.001). Multivariate analyses showed that the factors significantly affected the OS were CTP grade, tumor number > 3, and TRIPLET treatment (p < 0.001). Grade 3/4 adverse events occurred at a rate of 82.1% vs. 71.3% in TRIPLET and C-A groups, respectively.<BR><B>CONCLUSIONS: </B>The TRIPLET protocol has promising survival benefits in the management of patients with Ad-HCC, with acceptable safety.<BR><B>BACKGROUND: </B>The study has been retrospectively registered at Chinese Clinical Trial Registry ( https://www.chictr.org.cn/ , ChiCTR2300075828).